Bio-Rad Laboratories (BIO) Earnings Analysis

Bio-Rad Laboratories (BIO) next reports earnings on 2026-07-30, consensus EPS 1.75 USD. Last quarter (2026-04-30) it missed with EPS 1.89 USD vs 1.97 USD est (-4.1%). It has beaten estimates in 5/8 recent quarters (63%). Trailing P/E 50.08.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BIO next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate1.75 USD
Revenue estimate0.62B

BIO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-301.89 USD1.97 USD-4.1%Miss
2026-02-122.51 USD2.57 USD-2.3%Miss
2025-10-292.26 USD2.3 USD-1.7%Miss
2025-07-312.61 USD1.93 USD+35.2%Beat
2025-05-012.54 USD1.73 USD+46.8%Beat
2025-02-132.9 USD2.86 USD+1.4%Beat
2024-10-302.01 USD1.28 USD+57%Beat
2024-08-013.11 USD2.12 USD+46.7%Beat

Beat rate: 5/8 (63%) over reported quarters with consensus data.

BIO valuation and analyst view

Trailing P/E50.08
Trailing EPS6.262 USD
Price / book1.20
Dividend yield0.00%
Market cap8.29B
Analyst consensusBuy (8 buy / 6 hold / 0 sell)
Avg price target306.67 USD

Related research pages

Frequently asked questions

When is Bio-Rad Laboratories (BIO)'s next earnings date?

Bio-Rad Laboratories is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 1.75 USD and revenue estimate of 0.62B.

Did BIO beat earnings last quarter?

In its 2026-04-30 report, BIO posted EPS of 1.89 USD versus a 1.97 USD estimate — a miss of 4.1%.

What is BIO's earnings track record?

Over the last 8 reported quarters with consensus data, BIO beat estimates 5 times (63%).

What is BIO's current P/E ratio and EPS?

BIO trades at a trailing P/E of 50.08 on trailing EPS of 6.261592106239335 USD.

What do analysts rate BIO?

Analyst consensus is "Buy" across 14 ratings (1 strong buy, 7 buy, 6 hold, 0 sell, 0 strong sell). Average 12-month price target: 306.67 USD.